Top

Hereditary Cancer in Clinical Practice

Published in:

Open Access 01-12-2019 | Salpingo-Oophorectomy | Case report

A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China

Authors: Wenhui Li, Lei Li, Ming Wu

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2019

Abstract

Background

Little is known about the status of genetic counseling for ovarian cancer in China.

Case presentation

We report a four-generation Chinese family with several types of cancer. The proband was a patient with high-grade serous ovarian cancer (HGSOC) who was found to harbor a pathogenic BRCA1 variant. Cosegregation analysis identified 7 of 9 relatives with the same deleterious variant. One month after the genetic test, one female carrier 54 years of age was diagnosed with stage IVB HGSOC, and another female 55 years of age accepted risk-reducing salpingo-oophorectomy, which revealed occult cancer of the fallopian tube (Stage IA).

Conclusions

Genetic counseling and testing for ovarian cancer in China have fallen behind international trends. Innovative studies and practices are urgently needed to establish models for cancer screening, prevention and treatment.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef

Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst. 2002;94(18):1396–406.CrossRef

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, et al. Risks of breast, ovarian, and contralateral breast Cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317(23):2402–16.CrossRef

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Genetic/familial high-risk assessment: breast and ovarian. Version 2.2019 -2018. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

SGO Clinical Practice Statement: Next generation cancer gene panels versus gene by gene testing. 2014. https://www.sgo.org/clinical-practice/guidelines/next-generation-cancer-gene-panels-versus-gene-by-gene-testing/.

Bennett RL, French KS, Resta RG, Doyle DL. Standardized human pedigree nomenclature: update and assessment of the recommendations of the National Society of genetic counselors. J Genet Couns. 2008;17(5):424–33.CrossRef

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.CrossRef

Lee Y, Medeiros F, Kindelberger D, Callahan MJ, Muto MG, Crum CP. Advances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancer. Adv Anat Pathol. 2006;13(1):1–7.CrossRef

Li L, Qiu L, Wu M. A survey of willingness about genetic counseling and tests in patients of epithelial ovarian cancer. Zhonghua Yi Xue Za Zhi. 2017;97(43):3412–5.PubMed

10.

Qiu L, Li L, Wu M. Questionnaire survey on the attitude to genetic counseling and testing for gynecologic oncology by Chinese healthcare providers. J Reprod Med. 2018;27(1):49–54.

11.

Li A, Xie R, Zhi Q, Deng Y, Wu Y, Li W, Yang L, Jiao Z, Luo J, Zi Y, et al. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls. Gynecol Oncol. 2018;151(1):145–52.CrossRef

12.

Shi T, Wang P, Xie C, Yin S, Shi D, Wei C, Tang W, Jiang R, Cheng X, Wei Q, et al. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. Int J Cancer. 2017;140(9):2051–9.CrossRef

13.

Wu X, Wu L, Kong B, Liu J, Yin R, Wen H, Li N, Bu H, Feng Y, Li Q, et al. The first Nationwide multicenter prevalence study of germline BRCA1 and BRCA2 mutations in Chinese ovarian Cancer patients. Int J Gynecol Cancer. 2017;27(8):1650–7.CrossRef

14.

Kwong A, Wong CH, Shea C, Suen DT, Choi CL. Choice of management of southern Chinese BRCA mutation carriers. World J Surg. 2010;34(7):1416–26.CrossRef

15.

Kwong A, Chen JW, Shin VY. A new paradigm of genetic testing for hereditary breast/ovarian cancers. Hong Kong Med J. 2016;22(2):171–7.PubMed

16.

Steffen LE, Du R, Gammon A, Mandelblatt JS, Kohlmann WK, Lee JH, Buys SS, Stroup AM, Campo RA, Flores KG, et al. Genetic testing in a population-based sample of breast and ovarian Cancer survivors from the REACH randomized trial: cost barriers and moderators of counseling mode. Cancer Epidemiol Biomark Prev. 2017;26(12):1772–80.CrossRef

17.

Arts-de Jong M, de Bock GH, van Asperen CJ, Mourits MJ, de Hullu JA, Kets CM. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: a systematic review. Eur J Cancer. 2016;61:137–45.CrossRef

18.

Shipman H, Flynn S, MacDonald-Smith CF, Brenton J, Crawford R, Tischkowitz M, Hulbert-Williams NJ. Universal BRCA1/BRCA2 testing for ovarian Cancer patients is welcomed, but with care: how women and staff contextualize experiences of expanded access. J Genet Couns. 2017;26(6):1280–91.CrossRef

19.

Social G, Committee on Bioethics. Ethical and policy issues in genetic testing and screening of children. Pediatrics. 2013;131(3):620–2.CrossRef

20.

Lamb JD, Garcia RL, Goff BA, Paley PJ, Swisher EM. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194(6):1702–9.CrossRef

21.

Singer CF, Tan YY, Rappaport C. Identification and management of familial breast cancer in Austria. Horm Mol Biol Clin Invest. 2017;32(2). https://doi.org/10.1515/hmbci-2017-0025.

22.

Bellcross CA, Leadbetter S, Alford SH, Peipins LA. Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomark Prev. 2013;22(4):728–35.CrossRef

23.

Committee Opinion No ACOG. 727: Cascade testing: testing women for known hereditary genetic mutations associated with Cancer. Obstet Gynecol. 2018;131(1):e31–e4.CrossRef

24.

Pasick RJ, Joseph G, Stewart S, Kaplan C, Lee R, Luce J, Davis S, Marquez T, Nguyen T, Guerra C. Effective referral of low-income women at risk for hereditary breast and ovarian Cancer to genetic counseling: a randomized delayed intervention control trial. Am J Public Health. 2016;106(10):1842–8.CrossRef

25.

Randall TC, Armstrong K. Health care disparities in hereditary ovarian Cancer: are we reaching the underserved population? Curr Treat Options in Oncol. 2016;17(8):39.CrossRef

Title: A family pedigree of malignancies associated with BRCA1 pathogenic variants: a reflection of the state of art in China
Authors: Wenhui Li
Lei Li
Ming Wu
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Salpingo-Oophorectomy
Ovarian Cancer
Ovarian Cancer
Published in: Hereditary Cancer in Clinical Practice / Issue 1/2019
Electronic ISSN: 1897-4287
DOI: https://doi.org/10.1186/s13053-019-0126-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Diagnostic yield and clinical utility of a comprehensive gene panel for hereditary tumor syndromes

Genetic counselling and personalised risk assessment in the Australian pancreatic cancer screening program

Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations

Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)

Endometrioid endometrial cancer “recurring” as high-grade serous adenocarcinoma in the inguinal lymph nodes in a patient with germline MLH1 mutated Lynch syndrome: consequence or coincidence?

A focused 35-minute whole body MRI screening protocol for patients with von Hippel-Lindau disease

Keynote webinar | Spotlight on antibody–drug conjugates in cancer